企業プロフィール
ARS Pharmaceuticals 株価・ニュース・カタリスト
- ティッカー:
- SPRY
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
6.24 USD (+10.44%)
終値
最終更新: 2026年8月17日
884M USD
時価総額
株価変動の要因
As of Aug 17, 2026, SPRY closed up 10.4% at $6.24. No new same-company headline was identified in the current news window.
企業概要
Needle-Free Epinephrine Company
ARS Pharmaceuticals commercializes neffy, an epinephrine nasal spray for Type I allergic reactions, including anaphylaxis. Neffy is an approved needle-free emergency epinephrine treatment in the United States and European Union.
Neffy Commercialization
The company is building U.S. sales, payer access, prescription-refill programs, and pharmacy affordability support while expanding internationally through regional partners. Health Canada has approved neffy, with ALK responsible for Canadian commercialization.
Patient-Centered Delivery Strategy
The nasal formulation is intended to remove barriers associated with injectable epinephrine, including needle anxiety, complex administration, and hesitation during emergencies. ARS is building its commercial strategy around portability, ease of use, and broader willingness to carry treatment.
Intranasal Epinephrine Platform Expansion
Beyond emergency allergy treatment, ARS is evaluating intranasal epinephrine for acute flares of chronic spontaneous urticaria and has advanced the program into a Phase 2b study.
International Partnership Model
ARS uses regional partners to extend neffy beyond its direct U.S. commercial organization. These partners assume responsibility for local regulatory, distribution, and launch activities while broadening the geographic value of the product.
今後のカタリスト
- Interim Phase 2b data for intranasal epinephrine in chronic spontaneous urticaria in the first quarter of 2027.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。